Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.75 - $1.33 $15,423 - $27,351
-20,565 Reduced 37.01%
35,000 $32,000
Q1 2022

May 13, 2022

SELL
$1.29 - $4.04 $3,145 - $9,849
-2,438 Reduced 4.2%
55,565 $73,000
Q4 2021

Feb 11, 2022

SELL
$3.45 - $6.05 $57,711 - $101,204
-16,728 Reduced 22.38%
58,003 $224,000
Q3 2021

Nov 04, 2021

BUY
$5.53 - $9.28 $95,818 - $160,794
17,327 Added 30.18%
74,731 $417,000
Q2 2021

Aug 11, 2021

SELL
$7.84 - $12.6 $16,957 - $27,253
-2,163 Reduced 3.63%
57,404 $511,000
Q1 2021

May 13, 2021

SELL
$10.54 - $19.3 $342,518 - $627,192
-32,497 Reduced 35.3%
59,567 $755,000
Q4 2020

Feb 16, 2021

BUY
$12.79 - $17.1 $483,155 - $645,969
37,776 Added 69.58%
92,064 $1.28 Million
Q3 2020

Nov 12, 2020

BUY
$12.99 - $19.41 $21,732 - $32,472
1,673 Added 3.18%
54,288 $707,000
Q2 2020

Aug 13, 2020

BUY
$12.19 - $22.96 $46,919 - $88,373
3,849 Added 7.89%
52,615 $918,000
Q1 2020

May 14, 2020

SELL
$10.08 - $27.21 $2.28 Million - $6.14 Million
-225,771 Reduced 82.24%
48,766 $759,000
Q4 2019

Feb 14, 2020

BUY
$13.05 - $21.88 $182 - $306
14 Added 0.01%
274,537 $5.52 Million
Q3 2019

Nov 14, 2019

SELL
$14.12 - $23.44 $125,498 - $208,334
-8,888 Reduced 3.14%
274,523 $3.87 Million
Q2 2019

Aug 14, 2019

SELL
$13.21 - $27.29 $44,715 - $92,376
-3,385 Reduced 1.18%
283,411 $4.61 Million
Q1 2019

May 15, 2019

BUY
$12.46 - $22.05 $3 Million - $5.3 Million
240,381 Added 517.9%
286,796 $6.32 Million
Q4 2018

Feb 14, 2019

SELL
$15.43 - $32.7 $37,309 - $79,068
-2,418 Reduced 4.95%
46,415 $771,000
Q3 2018

Dec 21, 2021

BUY
$26.95 - $52.7 $43,308 - $84,688
1,607 Added 3.4%
48,833 $2.53 Million
Q3 2018

Nov 14, 2018

BUY
$26.95 - $52.7 $329,490 - $644,310
12,226 Added 34.93%
47,226 $2.45 Million
Q2 2018

Aug 14, 2018

BUY
$28.08 - $31.2 $982,799 - $1.09 Million
35,000 New
35,000 $999,000

Others Institutions Holding AVRO

# of Institutions
1
Shares Held
559K
Call Options Held
0
Put Options Held
0

About AVROBIO, Inc.


  • Ticker AVRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,773,900
  • Description
  • AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...
More about AVRO
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.